Daniel M. Freed

818 total citations
19 papers, 581 citations indexed

About

Daniel M. Freed is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Daniel M. Freed has authored 19 papers receiving a total of 581 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 8 papers in Oncology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Daniel M. Freed's work include Electron Spin Resonance Studies (4 papers), Protein Degradation and Inhibitors (4 papers) and Bone Tumor Diagnosis and Treatments (4 papers). Daniel M. Freed is often cited by papers focused on Electron Spin Resonance Studies (4 papers), Protein Degradation and Inhibitors (4 papers) and Bone Tumor Diagnosis and Treatments (4 papers). Daniel M. Freed collaborates with scholars based in United States, Singapore and Canada. Daniel M. Freed's co-authors include Mark A. Lemmon, Anatoly Kiyatkin, Nicholas J. Bessman, David S. Cafiso, Emanuel Salazar-Cavazos, Christopher C. Valley, Kathryn M. Ferguson, Diane S. Lidke, Patrick O. Byrne and Daniel J. Leahy and has published in prestigious journals such as Cell, Nature Communications and The Journal of Physical Chemistry B.

In The Last Decade

Daniel M. Freed

17 papers receiving 576 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel M. Freed United States 9 334 182 114 77 71 19 581
Scott T. Clarke United States 10 573 1.7× 92 0.5× 139 1.2× 56 0.7× 27 0.4× 22 920
Erik Hofman Netherlands 12 591 1.8× 123 0.7× 204 1.8× 132 1.7× 122 1.7× 15 1.0k
Samata Kakkad United States 18 290 0.9× 211 1.2× 162 1.4× 31 0.4× 129 1.8× 30 756
Gregory Weitsman United Kingdom 18 409 1.2× 288 1.6× 119 1.0× 83 1.1× 97 1.4× 35 792
Erika Kovács Hungary 9 645 1.9× 324 1.8× 256 2.2× 34 0.4× 113 1.6× 13 912
Srabani Bhaumik United States 12 593 1.8× 125 0.7× 111 1.0× 167 2.2× 63 0.9× 17 911
Julie Rothacker Australia 14 563 1.7× 370 2.0× 327 2.9× 37 0.5× 70 1.0× 25 888
Anupong Tangpeerachaikul United States 5 515 1.5× 96 0.5× 182 1.6× 22 0.3× 50 0.7× 15 723
Florian Baumgart Austria 13 266 0.8× 70 0.4× 57 0.5× 157 2.0× 77 1.1× 20 580
Erika Orbán Hungary 18 496 1.5× 185 1.0× 79 0.7× 14 0.2× 32 0.5× 34 753

Countries citing papers authored by Daniel M. Freed

Since Specialization
Citations

This map shows the geographic impact of Daniel M. Freed's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel M. Freed with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel M. Freed more than expected).

Fields of papers citing papers by Daniel M. Freed

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel M. Freed. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel M. Freed. The network helps show where Daniel M. Freed may publish in the future.

Co-authorship network of co-authors of Daniel M. Freed

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel M. Freed. A scholar is included among the top collaborators of Daniel M. Freed based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel M. Freed. Daniel M. Freed is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Raman, Renuka, Joan Levy, Daniel M. Freed, & Sean Ekins. (2025). Repurposing a Combination of Palbociclib and Afatinib Halts Chordoma Growth in a Mouse Model. 4(2). 91–96.
2.
Dolat, Lee, Wendy Leung, Joan Levy, et al.. (2023). Abstract 6195: Assessing replication stress as an actionable therapeutic opportunity in chordoma. Cancer Research. 83(7_Supplement). 6195–6195.
3.
Sharifnia, Tanaz, Mathias J. Wawer, Amy Goodale, et al.. (2023). Mapping the landscape of genetic dependencies in chordoma. Nature Communications. 14(1). 1933–1933. 17 indexed citations
4.
Dolat, Lee, et al.. (2023). Abstract 4865: Mechanisms of EGFR inhibitor sensitivity and resistance in chordoma. Cancer Research. 83(7_Supplement). 4865–4865. 1 indexed citations
5.
Kesari, Santosh, Feng Wang, Tiffany Juarez, et al.. (2023). Activity of pemetrexed in pre-clinical chordoma models and humans. Scientific Reports. 13(1). 7317–7317. 5 indexed citations
6.
Saffran, Douglas C., Tressa Hood, Nikolaus D. Obholzer, et al.. (2022). Abstract 2564: CDK9 inhibition via KB-0742 is a potential strategy to treat transcriptionally addicted cancers. Cancer Research. 82(12_Supplement). 2564–2564. 3 indexed citations
7.
Freed, Daniel M., et al.. (2022). Emerging target discovery and drug repurposing opportunities in chordoma. Frontiers in Oncology. 12. 1009193–1009193. 6 indexed citations
8.
9.
Freed, Daniel M., et al.. (2019). Abstract 4415: CDK4/6 inhibition with lerociclib (G1T38) delays acquired resistance to targeted therapies in preclinical models of non-small cell lung cancer. Cancer Research. 79(13_Supplement). 4415–4415. 2 indexed citations
10.
Goodwin, Craig M., Andrew M. Waters, Bjoern Papke, et al.. (2019). Abstract LB-287: Combination therapies with CDK4/6 inhibitors to treat KRAS-mutant pancreatic cancer. Cancer Research. 79(13_Supplement). LB–287. 1 indexed citations
11.
Liu, Lijun, Tarjani Thaker, Daniel M. Freed, et al.. (2018). Regulation of Kinase Activity in the Caenorhabditis elegans EGF Receptor, LET-23. Structure. 26(2). 270–281.e4. 11 indexed citations
12.
Freed, Daniel M., Nicholas J. Bessman, Anatoly Kiyatkin, et al.. (2017). EGFR Ligands Differentially Stabilize Receptor Dimers to Specify Signaling Kinetics. Cell. 171(3). 683–695.e18. 264 indexed citations
13.
Lemmon, Mark A., Daniel M. Freed, Joseph Schlessinger, & Anatoly Kiyatkin. (2016). The Dark Side of Cell Signaling: Positive Roles for Negative Regulators. Cell. 164(6). 1172–1184. 81 indexed citations
14.
Freed, Daniel M., Diego Alvarado, & Mark A. Lemmon. (2015). Ligand regulation of a constitutively dimeric EGF receptor. Nature Communications. 6(1). 7380–7380. 31 indexed citations
15.
Bessman, Nicholas J., Daniel M. Freed, & Mark A. Lemmon. (2014). Putting together structures of epidermal growth factor receptors. Current Opinion in Structural Biology. 29. 95–101. 43 indexed citations
16.
Freed, Daniel M., et al.. (2013). Monomeric TonB and the Ton Box Are Required for the Formation of a High-Affinity Transporter–TonB Complex. Biochemistry. 52(15). 2638–2648. 38 indexed citations
17.
18.
Jiménez, Ricardo H. Flores, Daniel M. Freed, & David S. Cafiso. (2011). Lipid and Membrane Mimetic Environments Modulate Spin Label Side Chain Configuration in the Outer Membrane Protein A. The Journal of Physical Chemistry B. 115(49). 14822–14830. 6 indexed citations
19.
Freed, Daniel M., P.S. Horanyi, Michael C. Wiener, & David S. Cafiso. (2010). Conformational Exchange in a Membrane Transport Protein Is Altered in Protein Crystals. Biophysical Journal. 99(5). 1604–1610. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Scott T. Clarke Breakdown of academic impact, for papers by Erik Hofman Breakdown of academic impact, for papers by Samata Kakkad Breakdown of academic impact, for papers by Gregory Weitsman Breakdown of academic impact, for papers by Erika Kovács Breakdown of academic impact, for papers by Srabani Bhaumik Breakdown of academic impact, for papers by Julie Rothacker Breakdown of academic impact, for papers by Anupong Tangpeerachaikul Breakdown of academic impact, for papers by Florian Baumgart Breakdown of academic impact, for papers by Erika Orbán
Rankless by CCL
2026